Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Interleukin-21 promotes germinal center reaction by skewing the follicular regulatory T cell to follicular helper T cell balance in autoimmune BXD2 mice.

Ding Y, Li J, Yang P, Luo B, Wu Q, Zajac AJ, Wildner O, Hsu HC, Mountz JD.

Arthritis Rheumatol. 2014 Sep;66(9):2601-12. doi: 10.1002/art.38735.

2.

Interleukin-encoding adenoviral vectors as genetic adjuvant for vaccination against retroviral infection.

Ohs I, Windmann S, Wildner O, Dittmer U, Bayer W.

PLoS One. 2013 Dec 4;8(12):e82528. doi: 10.1371/journal.pone.0082528. eCollection 2013.

3.

Combination of DNA prime--adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model.

Kosinska AD, Zhang E, Johrden L, Liu J, Seiz PL, Zhang X, Ma Z, Kemper T, Fiedler M, Glebe D, Wildner O, Dittmer U, Lu M, Roggendorf M.

PLoS Pathog. 2013;9(6):e1003391. doi: 10.1371/journal.ppat.1003391. Epub 2013 Jun 13.

4.

Prime/boost immunization with DNA and adenoviral vectors protects from hepatitis D virus (HDV) infection after simultaneous infection with HDV and woodchuck hepatitis virus.

Fiedler M, Kosinska A, Schumann A, Brovko O, Walker A, Lu M, Johrden L, Mayer A, Wildner O, Roggendorf M.

J Virol. 2013 Jul;87(13):7708-16. doi: 10.1128/JVI.00645-13. Epub 2013 May 1.

5.

Comparison of polystyrene nanoparticles and UV-inactivated antigen-displaying adenovirus for vaccine delivery in mice.

Johrden L, Tenbusch M, Lietz R, Bonsmann MS, Niezold T, Wildner O, Bayer W.

Virol J. 2013 Apr 5;10:108. doi: 10.1186/1743-422X-10-108.

6.

DNA prime-adenovirus boost immunization induces a vigorous and multifunctional T-cell response against hepadnaviral proteins in the mouse and woodchuck model.

Kosinska AD, Johrden L, Zhang E, Fiedler M, Mayer A, Wildner O, Lu M, Roggendorf M.

J Virol. 2012 Sep;86(17):9297-310. doi: 10.1128/JVI.00506-12. Epub 2012 Jun 20.

7.

Codelivery of the chemokine CCL3 by an adenovirus-based vaccine improves protection from retrovirus infection.

Lietz R, Bayer W, Ontikatze T, Johrden L, Tenbusch M, Storcksdieck Genannt Bonsmann M, Uberla K, Dittmer U, Wildner O.

J Virol. 2012 Feb;86(3):1706-16. doi: 10.1128/JVI.06244-11. Epub 2011 Nov 16.

8.

Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes.

Bayer W, Lietz R, Ontikatze T, Johrden L, Tenbusch M, Nabi G, Schimmer S, Groitl P, Wolf H, Berry CM, Uberla K, Dittmer U, Wildner O.

Retrovirology. 2011 Sep 26;8:75. doi: 10.1186/1742-4690-8-75.

9.

Vaccination with an adenoviral vector that encodes and displays a retroviral antigen induces improved neutralizing antibody and CD4+ T-cell responses and confers enhanced protection.

Bayer W, Tenbusch M, Lietz R, Johrden L, Schimmer S, Uberla K, Dittmer U, Wildner O.

J Virol. 2010 Feb;84(4):1967-76. doi: 10.1128/JVI.01840-09. Epub 2009 Dec 9.

10.

Transgene expression by oncolytic adenoviruses is modulated by E1B19K deletion in a cell type-dependent manner.

Rohmer S, Quirin C, Hesse A, Sandmann S, Bayer W, Herold-Mende C, Haviv YS, Wildner O, Enk AH, Nettelbeck DM.

Virology. 2009 Dec 20;395(2):243-54. doi: 10.1016/j.virol.2009.09.030. Epub 2009 Oct 25.

11.

Epithelial phenotype confers resistance of ovarian cancer cells to oncolytic adenoviruses.

Strauss R, Sova P, Liu Y, Li ZY, Tuve S, Pritchard D, Brinkkoetter P, Möller T, Wildner O, Pesonen S, Hemminki A, Urban N, Drescher C, Lieber A.

Cancer Res. 2009 Jun 15;69(12):5115-25. doi: 10.1158/0008-5472.CAN-09-0645. Epub 2009 Jun 2.

12.

Immunogenicity and efficacy of intradermal tattoo immunization with adenoviral vector vaccines.

Potthoff A, Schwannecke S, Nabi G, Hoffmann D, Grunwald T, Wildner O, Brockmeyer NH, Uberla K, Tenbusch M.

Vaccine. 2009 May 11;27(21):2768-74. doi: 10.1016/j.vaccine.2009.03.001. Epub 2009 Mar 13.

PMID:
19366575
13.

Enhancement of immunostimulatory properties of exosomal vaccines by incorporation of fusion-competent G protein of vesicular stomatitis virus.

Temchura VV, Tenbusch M, Nchinda G, Nabi G, Tippler B, Zelenyuk M, Wildner O, Uberla K, Kuate S.

Vaccine. 2008 Jul 4;26(29-30):3662-72. doi: 10.1016/j.vaccine.2008.04.069. Epub 2008 May 16.

PMID:
18538453
15.

Evaluation of the Friend Virus model for the development of improved adenovirus-vectored anti-retroviral vaccination strategies.

Bayer W, Schimmer S, Hoffmann D, Dittmer U, Wildner O.

Vaccine. 2008 Jan 30;26(5):716-26. Epub 2007 Dec 5.

PMID:
18160188
16.
17.

Evaluation of twenty-one human adenovirus types and one infectivity-enhanced adenovirus for the treatment of malignant melanoma.

Hoffmann D, Bayer W, Heim A, Potthoff A, Nettelbeck DM, Wildner O.

J Invest Dermatol. 2008 Apr;128(4):988-98. Epub 2007 Oct 25.

19.

Immunocompetent syngeneic cotton rat tumor models for the assessment of replication-competent oncolytic adenovirus.

Steel JC, Morrison BJ, Mannan P, Abu-Asab MS, Wildner O, Miles BK, Yim KC, Ramanan V, Prince GA, Morris JC.

Virology. 2007 Dec 5;369(1):131-42. Epub 2007 Aug 28.

20.

Improved glioblastoma treatment with Ad5/35 fiber chimeric conditionally replicating adenoviruses.

Hoffmann D, Meyer B, Wildner O.

J Gene Med. 2007 Sep;9(9):764-78.

PMID:
17640083
22.
23.
24.

Comparison of herpes simplex virus- and conditionally replicative adenovirus-based vectors for glioblastoma treatment.

Hoffmann D, Wildner O.

Cancer Gene Ther. 2007 Jul;14(7):627-39. Epub 2007 May 4.

PMID:
17479104
25.
26.

Evaluation of twenty human adenoviral types and one infectivity-enhanced adenovirus for the therapy of soft tissue sarcoma.

Hoffmann D, Heim A, Nettelbeck DM, Steinstraesser L, Wildner O.

Hum Gene Ther. 2007 Jan;18(1):51-62.

PMID:
17184155
29.

Synergy between expression of fusogenic membrane proteins, chemotherapy and facultative virotherapy in colorectal cancer.

Hoffmann D, Bangen JM, Bayer W, Wildner O.

Gene Ther. 2006 Nov;13(21):1534-44. Epub 2006 Jun 22.

PMID:
16791286
30.

Replication properties of human adenovirus in vivo and in cultures of primary cells from different animal species.

Jogler C, Hoffmann D, Theegarten D, Grunwald T, Uberla K, Wildner O.

J Virol. 2006 Apr;80(7):3549-58.

32.

In vitro pharmacodynamic evaluation of antiviral medicinal plants using a vector-based assay technique.

Esimone CO, Grunwald T, Wildner O, Nchinda G, Tippler B, Proksch P, Uberla K.

J Appl Microbiol. 2005;99(6):1346-55.

33.

Effects of the Ad5 upstream E1 region and gene products on heterologous promoters.

Hoffmann D, Jogler C, Wildner O.

J Gene Med. 2005 Oct;7(10):1356-66.

PMID:
15945123
34.

Clinical trials: the sensitizing side of ONYX-015.

Wildner O.

Gene Ther. 2005 Mar;12(5):386-7. No abstract available.

PMID:
19202637
35.

Characterization of virus isolates by particle-associated nucleic acid PCR.

Stang A, Korn K, Wildner O, Uberla K.

J Clin Microbiol. 2005 Feb;43(2):716-20.

36.

Inhibition of early steps in the lentiviral replication cycle by cathelicidin host defense peptides.

Steinstraesser L, Tippler B, Mertens J, Lamme E, Homann HH, Lehnhardt M, Wildner O, Steinau HU, Uberla K.

Retrovirology. 2005 Jan 18;2:2.

37.

Production of lentiviral vectors by transient expression of minimal packaging genes from recombinant adenoviruses.

Kuate S, Stefanou D, Hoffmann D, Wildner O, Uberla K.

J Gene Med. 2004 Nov;6(11):1197-205.

PMID:
15459964
38.

In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy in vitro and in vivo.

Okada T, Caplen NJ, Ramsey WJ, Onodera M, Shimazaki K, Nomoto T, Ajalli R, Wildner O, Morris J, Kume A, Hamada H, Blaese RM, Ozawa K.

J Gene Med. 2004 Mar;6(3):288-99.

PMID:
15026990
39.

Comparison of replication-selective, oncolytic viruses for the treatment of human cancers.

Wildner O.

Curr Opin Mol Ther. 2003 Aug;5(4):351-61. Review.

PMID:
14513677
40.
41.

Subcutaneous Administration of a Replication-Competent Adenovirus Expressing HSV-tk to Cotton Rats: Dissemination, Persistence, Shedding, and Pathogenicity.

Wildner O, Morris JC.

Hum Gene Ther. 2002 Jan 1;13(1):101-12. Erratum in: Hum Gene Ther 2002 Feb 10;13(3):484.

PMID:
11779414
42.

AV.TK-mediated killing of subcutaneous tumors in situ results in effective immunization against established secondary intracranial tumor deposits.

Okada T, Shah M, Higginbotham JN, Li Q, Wildner O, Walbridge S, Oldfield E, Blaese RM, Ramsey WJ.

Gene Ther. 2001 Sep;8(17):1315-22.

43.

Oncolytic viruses as therapeutic agents.

Wildner O.

Ann Med. 2001 Jul;33(5):291-304. Review.

PMID:
11491186
44.

Expansion of hepatic and hematopoietic stem cells utilizing mouse embryonic liver explants.

Monga SP, Tang Y, Candotti F, Rashid A, Wildner O, Mishra B, Iqbal S, Mishra L.

Cell Transplant. 2001 Jan-Feb;10(1):81-9.

PMID:
11294475
45.

Gene transfer of heat-shock protein 70 reduces infarct size in vivo after ischemia/reperfusion in the rabbit heart.

Okubo S, Wildner O, Shah MR, Chelliah JC, Hess ML, Kukreja RC.

Circulation. 2001 Feb 13;103(6):877-81.

PMID:
11171798
46.

Expansion of Hepatic and Hematopoietic Stem Cells Utilizing Mouse Embryonic Liver Explants.

Monga SPS, Tang Y, Candotti F, Rashid A, Wildner O, Mishra B, Iqbal S, Mishra L.

Cell Transplant. 2001 Jan;10(1):81-89. doi: 10.3727/000000001783986945.

PMID:
28880670
47.

Therapy of peritoneal carcinomatosis from colon cancer with oncolytic adenoviruses.

Wildner O, Morris JC.

J Gene Med. 2000 Sep-Oct;2(5):353-60.

PMID:
11045429
49.
50.

Supplemental Content

Loading ...
Support Center